PANUC Publications

 1.  Bekris LM, Galloway NM, Millard S, Lockhart D, Li G, Galasko DR, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Leverenz JB, Seubert P, Tsuang DW, Peskind ER, Yu CE. Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease. Neurobiol Aging 2011; 32:556 e13-23. PMCID: PMC3065534

 2.  Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 2010; 23:228-42. PMCID: PMC3044594

 3.  Caudle WM, Bammler TK, Lin Y, Pan S, Zhang J. Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease. Expert Rev Neurother 2010; 10:925-42. PMCID: PMC2913169

 4.  Darvas M, Fadok JP, Palmiter RD. Requirement of dopamine signaling in the amygdala and striatum for learning and maintenance of a conditioned avoidance response. Learn Mem 2011; 18:136-43. PMCID: PMC3056517

 5.  Darvas M, Palmiter. Contributions of striatal dopamine signaling to the modulation of cognitive flexibility. Biol Psychiatry 2011; 69:704-707. NIHMSID: NIHMS#296613

 6.  Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, Goodlett DR, Wang Y, Armaly J, Tumas V, Zabetian CP, Leverenz JB, Shi M, Zhang J. Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 2011; epub ahead of print. PMCID: PMC journal, in process.

 7.  Fadok JP, Darvas M, Dickerson TM, Palmiter RD. Long-term memory for pavlovian fear conditioning requires dopamine in the nucleus accumbens and basolateral amygdala. PLoS One 2010; 5:e12751. PMCID: PMC2939886

 8.  Guthrie CR, Greenup L, Leverenz JB, Kraemer BC. MSUT2 is a determinant of susceptibility to tau neurotoxicity. Hum Mol Genet 2011; 20:1989-99. PMCID: PMC3080609

 9.  Jayadev S, Nochlin D, Poorkaj P, Steinbart EJ, Mastrianni JA, Montine TJ, Ghetti B, Schellenberg GD, Bird TD, Leverenz JB. Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype. Ann Neurol 2011; 69:712-20. NIHMSID: NIHMS296614

10. Kay DM, Stevens CF, Hamza TH, Montimurro JS, Zabetian CP, Factor SA, Samii A, Griffith A, Roberts JW, Molho ES, Higgins DS, Gancher S, Moses L, Zareparsi S, Poorkaj P, Bird T, Nutt J, Schellenberg GD, Payami H. A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology 2010; 75:1189-94. PMCID: PMC3013490

11.  Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat Disord 2011; 17:61-4. PMCID: PMC3071582

12. Mata I, Wilhoite G, Yearout D, Bacon J, Cornejo M, Mazzetti P, Cosentino C, Torres L, Medina A, Medina-Colque A, Perez-Pastene C, Díaz-Grez F, Vilariño-Güell C, Venegas P, Miranda M, Godoy O, Layson L, Avello R, Dieguez E, Raggio V, Micheli F, Perandones C, Alvarez V, Segura-Aguilar J, Farrer M, Zabetian C, Ross O. Lrrk2 p.Q1111H substitution and Parkinson's disease in Latin America. Parkinsonism Relat Disord in press.

13. Mata IF, Shi M, Agarwal P, Chung KA, Edwards KL, Factor SA, Galasko DR, Ginghina C, Griffith A, Higgins DS, Kay DM, Kim H, Leverenz JB, Quinn JF, Roberts JW, Samii A, Snapinn KW, Tsuang DW, Yearout D, Zhang J, Payami H, Zabetian CP. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 2010; 67:1350-6. PMCID: PMC3010848

14. Mata IF, Yearout D, Alvarez V, Coto E, de Mena L, Ribacoba R, Lorenzo-Betancor O, Samaranch L, Pastor P, Cervantes S, Infante J, Garcia-Gorostiaga I, Sierra M, Combarros O, Snapinn KW, Edwards KL, Zabetian CP. Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson's disease. Mov Disord 2011; 26:819-23. PMCID: PMC3082603

15.  McMillan PJ, White SS, Franklin A, Greenup JL, Leverenz JB, Raskind MA, Szot P. Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease. Brain Res 2011; 1373:240-52. PMCID: PMC3038670

16.  Milatovic D, Montine TJ, Zaja-Milatovic S, Madison JL, Bowman AB, Aschner M. Morphometric analysis in neurodegenerative disorders. Curr Protoc Toxicol 2010; Chapter 12:Unit12 6. PMCID: PMC2855147

17.  Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010; 25:2682-5. PMCID: PMC2978754

18.  Montine TJ. Prevalence estimates for latent neurodegenerative disease. Toxicol Pathol 2011; 39:99-102. PMCID: PMC3062523

19. Poorkaj P, Raskind WH, Leverenz JB, Matsushita M, Zabetian CP, Samii A, Kim S, Gazi N, Nutt JG, Wolff J, Yearout D, Greenup JL, Steinbart EJ, Bird TD. A novel X-linked four-repeat tauopathy with Parkinsonism and spasticity. Mov Disord 2010; 25:1409-17. NIHMSID: NIHMS297839.

20. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D, Zhang J. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011; 69:570-80. NIHMSID: NIHMS294720

21. Shi M, Huber BR, Zhang J. Biomarkers for cognitive impairment in Parkinson disease. Brain Pathol 2010; 20:660-71. PMCID: PMC2881485

22. Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Leverenz JB, Zhang J. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett 2010; 480:78-82. PMCID: PMC2943649

23. Silbert LC, Kaye J. Neuroimaging and cognition in Parkinson's disease dementia. Brain Pathol 2010; 20:646-53. NIHMSID: NIHMS165062

24. Snapinn KW, Larson EB, Kawakami H, Ujike H, Borenstein AR, Izumi Y, Kaji R, Maruyama H, Mata IF, Morino H, Oda M, Tsuang DW, Yearout D, Edwards KL, Zabetian CP. The UCHL1 S18Y polymorphism and Parkinson's disease in a Japanese population. Parkinsonism Relat Disord 2011; epub ahead of print. NIHMSID: NIHMS276782

25. Snyder LR, Hoggard JC, Montine TJ, Synovec RE. Development and application of a comprehensive two-dimensional gas chromatography with time-of-flight mass spectrometry method for the analysis of L-beta-methylamino-alanine in human tissue. J Chromatogr A 2010; 1217:4639-47. PMCID: PMC2901168

26. Sonnen JA, Cruz KS, Hemmy LS, Woltjer R, Leverenz JB, Montine KS, Jack CR, Kaye J, Lim K, Larson EB, White L, Montine TJ. Ecology of aging human brain.  Arch Neurol, in press

27. Sonnen JA, Larson EB, Walker RL, Haneuse S, Crane PK, Gray SL, Breitner JC, Montine TJ. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology 2010; 75:1203-10. PMCID: PMC3013492

28. Sonnen JA, Postupna N, Larson EB, Crane PK, Rose SE, Montine KS, Leverenz JB, Montine TJ. Pathologic correlates of dementia in individuals with Lewy body disease. Brain Pathol 2010; 20:654-9. PMCID: PMC2881486

29. Wall VZ, Parker JG, Fadok JP, Darvas M, Zweifel L, Palmiter RD. A behavioral genetics approach to understanding D1 receptor involvement in phasic dopamine signaling. Mol Cell Neurosci 2011; 46:21-31. PMCID: PMC3035386

30. Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Edwards KL, Snapinn KW, Goldstein DS, Shi M, Zhang J. Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol 2011; 178:1509-16. PMCID: PMC3078443

31. Watson GS, Leverenz JB. Profile of cognitive impairment in Parkinson's disease. Brain Pathol 2010; 20:640-5. PMCID: PMC3049172